Treatment of Perforated Peptic Ulcer with Healthcare-Associated Intra-Abdominal Infection and Normal Renal Function (Non-Critically Ill)
Clinical Scenario
This protocol covers the management of perforated peptic ulcer complicated by healthcare-associated intra-abdominal infection in patients who are not critically ill and have normal renal function — a distinct presentation where both antibiotic selection and treatment duration differ from community-acquired or critically ill cases.
Key Clinical Consideration
Healthcare-associated intra-abdominal infections carry an elevated risk of multidrug-resistant organisms (MDROs), which directly shapes empiric antibiotic choice. Normal renal function in this setting is an important modifier of the therapeutic approach.
Treatment Approach Partial — full protocol below
Management uses an empiric broad-spectrum antibiotic regimen, with the specific agent selected according to the patient's individual risk factors for MDRO pathogens. The full protocol stratifies antibiotic options — including carbapenem-sparing regimens — based on those risk factors. Complete drug selection, sequencing, and duration guidance are in the structured protocol.
Treatment Goal
Normalization of inflammatory markers, targeting a short course of antibiotic therapy (3–5 days).
References
- Healthcare-associated
- 1) Empiric antimicrobial regimens for non-critically ill patients with IAIs and normal renal function:
- Piperacillin/tazobactam 4.5 g 6-hourly
- In patients at higher risk for infection with MDROs including recent antibiotic exposure, patient living in a nursing home or long-stay care with an indwelling catheter or postoperative infections
- Meropenem 1 g 8-hourly +/− ampicillin 2 g 6-hourly or Doripenem 500 mg 8-hourly +/− ampicillin 2 g 6-hourly or Imipenem/Cilastatin 1 g 8-hourly or As a carbapenem-sparing regimen piperacillin/tazobactam 4.5 g 6-hourly + tigecycline 100 mg initial dose, then 50 mg 12-hourly
- In patients with perforated peptic ulcer, we suggest a short-course (3–5 days or until inflammatory markers normalize) antibiotic therapy (weak recommendation based on low-quality evidences, 2C).
View source ↗